$GANX

BTIG reiterated a Buy rating and $5.00 price target for Gain Therapeutics (GANX), citing positive Phase 1b trial data for GT-02287 in Parkinson’s disease. The stock has a Strong Buy consensus, with targets ranging from $5 to $8. The company plans to submit a Phase 2 protocol to the FDA and initiate the study in Q1 2027. GANX reported strong financial health, with a current ratio of 4.36. H.C. Wainwright also reiterated a Buy rating with an $8.00 target.

Gain Therapeutics (GANX) reported stable motor function scores in Parkinson’s patients after 12 months of rexaceract treatment in a Phase 1b trial, with no significant safety issues. The company plans to submit a Phase 2 study protocol to the FDA soon. Participants showed stabilization in MDS-UPDRS motor scores, with no clinically meaningful progression of symptoms. Both high and low baseline GluSph groups benefited, and adverse events decreased over time.

Gain Therapeutics (GANX) presented Phase 1b data showing that 12-month administration of rexaceract stabilized MDS-UPDRS motor scores in Parkinson’s disease patients, with no disease progression observed. The company plans to submit a Phase 2 study protocol to the FDA and initiate the trial in Q1 2027. Rexaceract demonstrated a favorable safety profile and potential disease-modifying activity.

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 1, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. The post

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Principal Financial Officer On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, pri

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update BETHESDA, Md., August 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and dev

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001819411 0001819411 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

HC Wainwright has revised its Q1 2026 earnings estimates for Gain Therapeutics (NASDAQ:GANX), now projecting a smaller loss per share of ($0.13), an improvement from their previous forecast of ($0.15). The firm maintains a "Buy" rating and an $8.00 price target for the stock. This update follows Gain Therapeutics' recent earnings report where they surpassed consensus estimates by reporting ($0.11) EPS against a projected ($0.14).

Gain Therapeutics reported its 2025 financial results, showing a narrowed net loss of $20.2 million compared to $20.4 million in 2024, with its cash reserves more than doubling to $20.8 million. The company also provided an update on its lead Parkinson’s disease candidate, GT-02287, highlighting encouraging Phase 1b data with central nervous system target engagement and stable or improved clinical scores. Gain Therapeutics anticipates significant milestones in 2026, including IND clearance for GT-02287 and the initiation of a Phase 2 clinical trial.

Gain Therapeutics is scheduled to present key clinical program updates at the Oppenheimer Healthcare Conference, focusing on its lead candidate GT-02287 for Parkinson's disease. The presentation, set for tomorrow, is highly anticipated for potential biomarker data that could support GT-02287's profile as a disease-modifying therapy. The market will be closely watching for implications on its Phase 2b study strategy and the stock's future movements, especially ahead of the company's Q4 earnings release on March 26.